Combination therapies for fungal pathogens
AssigneesDuke University, The Johns Hopkins University
InventorsJoseph Heitman, Miguel Arevalo-Rodriguez, Xuewen Pan, Jef Boeke
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of treating fungal infections with a drug combination: a first compound that inhibits the activity or expression of the protein FKBP12 and a second compound that inhibits the activity or expression of homoserine dehydrogenase. Evidence indicates that dual inhibitors of proteins FKBP12 and homoserine dehydrogenase are lethal to fungi. Such an approach should be minimally toxic since this combination therapy targets a biosynthetic pathway that is conserved in fungi but not in mammals.
Claims15
A method for treating a pathogenic fungal infection in a mammalian subject comprising the step of administering to the subject a composition comprising a FKBP12 inhibitor and a homoserine dehydrogenase inhibitor.
A method for treating a pathogenic fungal infection comprising providing a mammalian subject infected with a fungus resistant to one or more other antifungal therapies and administering to said subject a composition comprising a FKBP12 inhibitor and a homoserine dehydrogenase inhibitor.
A method for treating a pathogenic fungal infection in a mammalian subject comprising the step of administering to the subject a composition comprising:
- a) a compound selected from FK506, L-683,590, L-685,818, and rapamycin;
- and
- b) RI-331.
Dependencies are inferred from the claim text.